| Cristine Teresa Moore, | |
|
3515 Heartwood Place, Anchorage, AK 99504 | |
| (907) 338-2233 | |
| Not Available |
| Full Name | Cristine Teresa Moore |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 3515 Heartwood Place, Anchorage, Alaska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437311602 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (Alaska) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Cristine Teresa Moore, 3515 Heartwood Pl, Anchorage, AK 99504-3902 Ph: (907) 338-2233 | Cristine Teresa Moore, 3515 Heartwood Place, Anchorage, AK 99504 Ph: (907) 338-2233 |
News Archive
Drug makers Bayer AG and Johnson & Johnson's new blood clot preventing drug can provide life-saving benefits at very low doses in patients who suffer from acute coronary syndrome finds a new clinical trial.
In letters to leaders of the U.S. House of Representatives and U.S. Senate today, the American College of Occupational and Environmental Medicine expressed its strong concerns about the effect of proposed funding cuts to the National Institute for Occupational Safety and Health - which ACOEM says will devastate the nation's supply of new physicians trained to treat injured and ill workers.
Inherited mutations in the BRCA1 or BRCA2 tumor suppressor genes are by far the most frequent contributors to hereditary cancer risk in the human population, often causing breast or ovarian cancer in young women of child-bearing age.
Boehringer Ingelheim will present a pooled analysis of new data from the Phase 3 UniTinA-asthma® program at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona. The data from the individual MezzoTinA-asthma® Phase 3 studies (NCT01340209 and NCT00565266), from which the pooled data are derived, show the addition of tiotropium delivered via the Respimat® inhaler to medium-dose maintenance inhaled corticosteroid (ICS) therapy (defined as 400-800 µg budesonide/day or equivalent) improved lung function and provided sustained bronchodilation over 24 hours in patients with moderate asthma and airflow limitation. Tiotropium is being investigated to determine the medicine's efficacy in treating asthma patients and is not currently approved for this indication.
› Verified 6 days ago
Kathryn Cross, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 12350 Industry Way, 202, Anchorage, AK 99515 Phone: 907-301-4588 | |
Tracey Keaton, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6927 Old Seward Hwy Ste 100, Anchorage, AK 99518 Phone: 907-345-0050 | |
Christal Hays, MS CCC SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 4441 Diplomacy Dr, Anchorage, AK 99508 Phone: 907-729-8800 | |
Mrs. Lisa J.c. Rayes, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4048 Laurel St Ste 303, Anchorage, AK 99508 Phone: 907-562-4550 | |
Lian Liew Tan, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4155 Tudor Centre Dr, Suite #103, Anchorage, AK 99508 Phone: 907-854-8624 | |
Mrs. Yvonne Marie San Juan, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4241 B St Ste 301, Anchorage, AK 99503 Phone: 907-727-0935 Fax: 907-276-7529 | |
Speak From The Heart Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3351 W 84th Ave, Anchorage, AK 99502 Phone: 907-390-0492 |